What reviewers say about Cellgorithmics
What is Cellgorithmics?
Cellgorithmics is a biotechnology company located in Chicago, Illinois, that develops the Syntax platform to program stem cell differentiation. Their proprietary Cellgorithm technology mimics human development to generate diverse functional cell types for therapies. The company offers a collaboration business model with upfront R&D payments, milestone-based fees, and royalties to make discovery faster and less costly.
How does Cellgorithmics' technology speed up stem cell research?
The company's website states that their technology can cut differentiation timelines from months to days, enabling faster process optimization and preclinical studies. This accelerated discovery increases the diversity of cell types that maintain native function, which expands the range of diseases they can address. By reducing manufacturing costs and variability, they aim to improve patient access and scalability for biopharma partners.
What do reviewers say about the website and support?
Multiple reviewers on Trustburn praise the user-friendliness of the Cellgorithmics website and the responsiveness of their customer support team. Users consistently mention that the site is easy to navigate and that support staff addressed queries efficiently. These positive experiences have led to high satisfaction ratings and strong recommendations from customers.
Where is Cellgorithmics located and how can I contact them?
Cellgorithmics operates under the brand Syntax Bio and is based at 400 N Aberdeen, Floor 9 in Chicago, IL 60642. They can be reached via the email address [email protected] for inquiries. The company also maintains a presence on LinkedIn for professional networking and updates.
Who are the key people behind Cellgorithmics?
The company's leadership includes CEO John Craighead, PhD, and Co-Founders Ryan Clarke, PhD, and Niko Balanis, PhD. Their board of directors features investors and advisors such as Pete Bodine from Allegis Capital and Satoshi Konagai from Astellas Venture Management. This structure supports their mission to reinvent cellular differentiation processes.
What are the terms of Cellgorithmics' collaboration model?
Syntax Bio's collaboration model is designed for biopharma discovery partnerships, offering a capital-efficient approach to development. The terms include upfront R&D payments, milestone-based fees, and royalties, allowing partners to capture significant downstream economics. This structure helps make discovery faster and less costly for existing cell therapy programs.
What specific features does the Cellgorithm technology offer?
The company's proprietary Cellgorithm technology is described as a force multiplier for existing cell therapy programs. It provides customizable, epigenetic instructions to program step-wise cellular differentiation processes efficiently. This approach reduces growth factor requirements and mimics native human development to generate functional cell types.
What major breakthroughs has Cellgorithmics achieved?
According to a press release, Syntax Bio successfully programmed stem cells toward pancreatic beta cells in just four days. This achievement demonstrates their ability to accelerate discovery and optimize differentiation processes rapidly. Such speed translates to faster time to IND pipeline expansion and broader indication spaces.
What is the core mission of Cellgorithmics?
The company's mission is to overcome longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation. They aim to enable new product opportunities and address larger disease areas through a wide diversity of cell types. Their goal is to make discovery faster, less costly, and scalable while improving patient access.
What is the background of Cellgorithmics' founding and team?
The company's history includes founding by Ryan Clarke, PhD, and Niko Balanis, PhD, with John Craighead, PhD as CEO. They have built a team of scientific advisors and investors to support their technology development. Their growth has been supported by partnerships with organizations like Astellas Venture Management and DCVC Bio.
How does Cellgorithmics reduce manufacturing costs?
The company's website states that their technology reduces growth factor requirements and uses fewer media steps in differentiation. This efficiency helps lower manufacturing costs and decreases variability in the production of functional cell types. These improvements are critical for scaling up cell therapy programs effectively.
How does Cellgorithmics ensure cell functionality?
The company's technology is designed to mimic human development to generate a wide diversity of functional cell types. This capability allows them to address larger disease areas and expand the indication space for their products. By pre-programming sequential regulation, they ensure cells maintain native function throughout the process.
How is Cellgorithmics rated on Trustburn?
On Trustburn, Cellgorithmics has a rating of 4.1 out of 5 based on 9 reviews.
Is Cellgorithmics on social media?
Cellgorithmics has official profiles on Linkedin.
Post your question publicly — other visitors, and whoever manages this page, can answer. It will be visible on this page.
Want to hear about this company again? Follow it and we’ll email you when a new review appears.
Based on reviews, listing data and the company's website. Verify anything important with the company directly.
Questions & Answers
No questions yet — be the first to ask.
Sign in to post
Your text is saved — you'll come right back to post.
Don't have an account? Create one
News & Press
No news yet. This is where the business shares its own updates and press.
Photos
No photos yet. Photos shared by reviewers will show up here.
About Cellgorithmics
- Website
- cellgorithm.com
- Categories
- Biotechnology
